Provention Bio is a clinical stage biopharmaceutical dedicated to sourcing, developing and commercializing novel therapeutics.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease.Their “predict and prevent” model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears or progresses. As such, we believe Provention is well-positioned to become a leader in a new biopharmaceutical category centered on the interception of disease, offering the potential to reduce the high-morbidity, mortality, patient suffering and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. Provention has been carefully conceived, founded and positioned to be at the forefront of this pioneering new paradigm in medicine. They believe Provention’s business model, coupled with our expertise in translational medicine, immunology and the design and execution of rapid go/no-go clinical trials, will enable us to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 31, 2022 | Post-IPO Debt | $125M | 1 | Hercules Capital | — | Detail |
Jul 7, 2022 | Post-IPO Equity | $60M | 2 | Armistice Capital Sessa Capital | — | Detail |
Jan 13, 2021 | Post-IPO Equity | $100M | — | — | — | Detail |
Jun 22, 2020 | Post-IPO Equity | $110.10M | — | — | — | Detail |
Jul 19, 2018 | IPO | $63.90M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |
Armistice Capital | Yes | Post-IPO Equity |
Sessa Capital | Yes | Post-IPO Equity |
Johnson & Johnson Innovation | Yes | Series A |
JDRF T1D Fund | — | Series A |
MDB Capital Group | — | Series A |